Author: Ramona Adams|| Date Published: September 14, 2016
Mylan Pharmaceuticals (Nasdaq: MYL) has won a potential $121.5 million contract from the Defense Logistics Agency to provide lidocaine 5 percent patch, a medicine designed for the treatment of post-herpetic neuralgia pain.
Mylan will supply the medical product to the departments of Defense and Veterans Affairs as well as the Indian Health Services and Federal Bureau of Prisons under the firm-fixed-price contract, DoD said Tuesday.
DoD noted the contract has one base year and four option years.
The company will perform work in West Virginia, Vermont and North Carolina through Sept. 12, 2021.
DLA Troop Support received four proposals for the contract and will obligate defense working capital funds in fiscal year 2017 through fiscal 2021.
Aerospace and defense technology company Merlin has closed its business combination with Inflection Point Acquisition Corp. IV, a special purpose acquisition company…
Raytheon, an RTX business, has received a potential $212.1 million cost-plus-fixed-fee contract to provide operations and maintenance services for a relocatable over-the-horizon…
Jim Kelly, senior systems engineering manager at HPE Juniper Networking, said agentic artificial intelligence could help government agencies move toward…
AeroVironment has acquired Empirical Systems Aerospace, or ESAero, a producer of unmanned aircraft systems and advanced air mobility platforms, or AAM,…
Mylan Pharmaceuticals (Nasdaq: MYL) has won a potential $121.5 million contract from the Defense Logistics Agency to provide lidocaine 5 percent patch, a medicine designed for the treatment of post-herpetic neuralgia pain.
